Burke Michael J, Cohn Susan L
Division of Hematology/Oncology/Transplant, Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Pediatr Blood Cancer. 2008 Mar;50(3):679-80. doi: 10.1002/pbc.21009.
Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.
眼阵挛-肌阵挛综合征（OMS）是一种罕见的副肿瘤综合征，发生于2%-3%的神经母细胞瘤患者中。该综合征的病因被认为是免疫介导的，但确切机制仍不清楚。迫切需要改进我们目前治疗OMS患者的策略，因为许多患者采用目前的治疗方法会出现严重的长期神经功能缺损和行为障碍。已证明能改善这些患者症状的治疗方法包括促肾上腺皮质激素和皮质类固醇，以及静脉注射丙种球蛋白和血浆置换。我们报告了利妥昔单抗治疗一名神经母细胞瘤合并OMS患者的经验。
